Synoviorthesis induced by XXXX in @entity2720 : a report of 24 treated joints.

@entity1 @entity82 @entity548 @entity447 @entity603 @entity1215 @entity158 @entity2720 @entity5631
Intra-articular @entity548 is the clinical hallmark of @entity447 . Synoviorthesis, the intra-articular injection of chemical or radioactive substances in order to produce @entity82 of the hypertrophied synovium, has proved effective in the treatment of chronic @entity603 . Between December 2006 and July 2007, we treated 21 @entity1 with @entity2720 by synoviorthesis with @entity1215 once a week. The procedures were performed on 14 knees, five elbows, four ankles, and one shoulder (24 joints and 113 injections). The mean age was 16.7 years (range, 7-49 years). According to the Fernandez-Palazzi classification, synoviorthesis was considered satisfactory (excellent or good) in 21 (87.5%) joints and unsatisfactory (fair or poor) in three (12.5%). A mean reduction of 6.3 @entity548 episodes per month was obtained (P < 0.0001). The mean @entity158 score was reduced from 2.62 (range, 2-3; SD, 0.49) before treatment to 0.79 (range, 0-2; SD, 0.65) after treatment. The mean World Federation of @entity447 (WFH) score was 5.45 (range, 2-8) before synoviorthesis and 3.5 (range, 1-7) after treatment. This method effectively reduced @entity5631 and @entity158 and also improved the range of motion in @entity1 with @entity2720 . Chemical synoviorthesis with @entity1215 appears to be efficient, inexpensive, and simple and also especially practical in developing countries where radioactive agents are not easily available.
